Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE vs DEMADEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that is added to deter intravenous abuse.
Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Treatment of opioid dependence (FDA-approved),Maintenance therapy for opioid use disorder,Off-label: chronic pain management (limited use)
Edema associated with heart failure, hepatic cirrhosis, and renal disease,Hypertension (off-label)
Sublingual tablet: initially 2/0.5 mg buprenorphine/naloxone, titrated to maintenance 4/1 mg to 24/6 mg once daily; administered sublingually as a single daily dose.
Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.
Buprenorphine: terminal half-life 24-60 hours (mean ~37h) due to slow dissociation from mu-opioid receptors; naloxone: ~2-12 hours (mean ~1-2h IV, slightly longer sublingual).
The terminal elimination half-life is approximately 4 hours (range 2-8 hours) in patients with normal renal function. In renal impairment (creatinine clearance <30 m L/min), half-life is prolonged to 10-12 hours due to reduced renal clearance. In hepatic cirrhosis, half-life may be extended to 8-9 hours due to decreased metabolism.
Buprenorphine is primarily metabolized by CYP3A4 to norbuprenorphine; naloxone is metabolized by UDP-glucuronosyltransferases (UGT1A1, UGT1A3).
Primarily hepatic via CYP450 enzymes, with minimal renal clearance.
Buprenorphine: ~70% fecal via biliary excretion, ~30% renal as unchanged drug and metabolites. Naloxone: primarily hepatic metabolism, ~50% renal excretion of metabolites within 6h.
Approximately 50% of the absorbed dose is excreted unchanged in the urine via glomerular filtration and active tubular secretion. The remainder undergoes hepatic metabolism to glucuronide conjugates and minor oxidative metabolites, with biliary excretion of metabolites (about 30-40% of the dose) eliminated in feces. Renal clearance is the primary route for the parent drug.
Buprenorphine: ~96% bound to alpha- and beta-globulins; naloxone: ~45% bound to albumin (primarily).
Torsemide (DEMADEX) is extensively bound to plasma proteins, primarily albumin, with a protein binding of >99%.
Buprenorphine: Vd ~2.5-4.0 L/kg (large distribution due to lipophilicity); naloxone: Vd ~2.0 L/kg.
The apparent volume of distribution (Vd) is approximately 0.16 L/kg (range 0.12–0.20 L/kg), indicating distribution primarily within extracellular fluid. Vd is increased in conditions with expanded extracellular volume (e.g., heart failure, cirrhosis, nephrotic syndrome).
Sublingual buprenorphine: ~30-50% (avoid first-pass); sublingual naloxone: ~10% (low); IV: 100% both.
Oral bioavailability is approximately 80–90%, with minimal first-pass metabolism. Absorption is rapid and not significantly affected by food.
For GFR <30 m L/min: use with caution, dose reduction may be necessary; avoid in severe impairment (creatinine clearance <15 m L/min) due to naloxone accumulation.
GFR <20 m L/min/1.73 m²: Use with caution; may require dose reduction or discontinuation due to accumulation. GFR 20-50: No adjustment needed. GFR >50: No adjustment.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce starting dose by 50%, monitor for oversedation. Child-Pugh Class C: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% or extend interval. Child-Pugh C: Avoid use or reduce dose by 75%.
Not approved for pediatric patients under 16 years for opioid use disorder; safety and efficacy not established.
Neonates and infants: 0.1-0.2 mg/kg/dose IV/IM once daily. Children: Oral: 0.5-1 mg/kg once daily; IV/IM: 0.1-0.2 mg/kg/dose once daily. Maximum: 5 mg/day.
Initiate at lower end of dosing range (e.g., 2/0.5 mg sublingually once daily) due to increased sensitivity and potential for hepatic/renal impairment; titrate slowly and monitor for CNS depression.
Start at lower end of dose range (2.5-5 mg orally once daily); titrate slowly due to increased sensitivity and renal impairment risk.
Risk of respiratory depression, particularly in patients using other CNS depressants, and risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
None.
Respiratory depression risk with intravenous administration,Hepatotoxicity (elevated liver enzymes, hepatic failure),Adrenal insufficiency with chronic use,Interaction with benzodiazepines and other CNS depressants,Precipitation of withdrawal in opioid-dependent patients if administered too soon after last opioid use,Dependence and abuse potential (Schedule III controlled substance),Neonatal opioid withdrawal syndrome if used during pregnancy
Hypotension and volume depletion,Electrolyte imbalances (hypokalemia, hyponatremia, hypochloremia),Ototoxicity (especially with rapid IV administration or high doses),Hyperuricemia,Sulfonamide allergy cross-reactivity
Hypersensitivity to buprenorphine or naloxone,Severe respiratory insufficiency (e.g., acute asthma, COPD),Severe hepatic impairment,Patients with acute intoxication (alcohol, opioids, benzodiazepines),Concurrent use of MAO inhibitors (relative contraindication)
Anuria,Severe electrolyte depletion,Hypersensitivity to sulfonamides or bumetanide (Demadex is a sulfonamide derivative)
No significant food interactions; grapefruit juice may increase buprenorphine levels but not considered clinically relevant; alcohol is contraindicated due to additive CNS depression; take on an empty stomach or with food if GI upset occurs.
Avoid excessive licorice intake (glycyrrhizin) as it can exacerbate hypokalemia. Limit sodium-rich foods (processed foods, canned soups) to enhance diuretic effect and control edema. Increase potassium-rich foods (bananas, oranges, potatoes) unless on a potassium-sparing medication. Avoid grapefruit juice as it may affect metabolism.
Pregnancy category C: First trimester: Limited data; no clear evidence of major malformations, but opioid exposure may be associated with neural tube defects in some studies. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use. No known specific teratogenicity; however, maternal opioid use may lead to fetal growth restriction, preterm birth, and stillbirth. Buprenorphine/naloxone is preferred over methadone in pregnancy due to less neonatal respiratory depression and NOWS severity.
DEMADEX (torsemide) is a loop diuretic. Human data are limited. In animal studies, high doses caused fetal resorptions and maternal toxicity. First trimester: insufficient human data; avoid unless benefit outweighs risk. Second/third trimester: risk of fetal oligohydramnios, renal impairment, and hypovolemia; use only if clearly needed.
Limited data; buprenorphine and naloxone are excreted into breast milk in low concentrations. The M/P ratio for buprenorphine is approximately 0.5–2.5, with high interindividual variability. Naloxone has poor oral bioavailability, reducing infant exposure. Benefits of breastfeeding likely outweigh risks if mother is stable on treatment. Monitor infant for sedation, respiratory depression, and adequate weight gain. Avoid use during breastfeeding in cases of high maternal doses or concurrent substance abuse.
Torsemide is excreted in breast milk in small amounts; M/P ratio not reported. Due to potential for diuresis, electrolyte imbalance, and allergic reactions in the infant, caution is recommended. Alternative diuretics with more safety data are preferred.
Pregnancy may require dose increases due to increased plasma volume, enhanced clearance, and changes in protein binding. Buprenorphine is extensively metabolized by CYP3A4, which may be induced during pregnancy. Aim to maintain trough levels to prevent withdrawal. Usually, doses are adjusted based on clinical response (withdrawal symptoms, cravings). No fixed dose adjustment; individual titration is necessary. Higher doses (up to 50% increase) may be needed in late pregnancy. Postpartum, doses should be tapered back to prepregnancy levels gradually.
Dosing may need adjustment due to increased plasma volume and GFR in pregnancy. Start at lowest effective dose. Monitor diuretic response and electrolyte balance; dose titration may be required. Postpartum, drug elimination may return to prepregnancy kinetics.
Avoid in patients with known respiratory insufficiency or acute opioid intoxication; use with caution in hepatic impairment; buprenorphine has a ceiling effect for respiratory depression; naloxone component prevents IV abuse; monitor for precipitated withdrawal if initiated too soon after last opioid use; requires at least 12 hours since last short-acting opioid or 24-72 hours for long-acting opioids; can cause QT prolongation at high doses; sublingual absorption is critical; consider dose adjustment in renal impairment.
DEMADEX (torsemide) is a loop diuretic with high bioavailability (80-100%) and a longer half-life (3-4 hours) than furosemide, allowing once-daily dosing. It is primarily metabolized by CYP2C9, so caution is needed with CYP2C9 inhibitors like amiodarone. Monitor for ototoxicity at high doses or rapid infusion. Hypokalemia risk persists; consider potassium supplementation or aldosterone antagonist. Use cautiously in sulfonamide allergy due to potential cross-sensitivity.
Place the tablet/film under the tongue until fully dissolved; do not chew, swallow, or crush.,Do not use alcohol or other sedatives (benzodiazepines, muscle relaxants, sleeping pills) as this can cause severe respiratory depression or coma.,Keep out of reach of children and pets; accidental ingestion is life-threatening.,Avoid driving or operating machinery until you know how the medication affects you.,Do not stop suddenly; withdrawal symptoms can occur; taper under medical supervision.,Store at room temperature away from moisture and heat.,Tell all healthcare providers you are taking this medication before any surgery or new prescriptions.,Seek emergency help if you experience difficulty breathing, chest pain, or signs of allergic reaction (rash, swelling).,If you miss a dose, skip it; do not double dose.
Take DEMADEX exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Weigh yourself daily and report sudden weight gain or loss of more than 2-3 pounds in a day.,Avoid alcohol and beverages containing caffeine as they may increase dehydration.,Do not take DEMADEX with licorice (which can worsen hypokalemia) or with high-sodium antacids.,Report signs of hearing loss, ringing in the ears, dizziness, or muscle cramps immediately.,Stand up slowly to prevent dizziness from low blood pressure.,Monitor for signs of dehydration: dry mouth, thirst, infrequent urination.
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE vs DEMADEX, answered by our medical review team.
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is a Opioid Antagonist that works by Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that is added to deter intravenous abuse.. DEMADEX is a Loop Diuretic that works by Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE and DEMADEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is: Sublingual tablet: initially 2/0.5 mg buprenorphine/naloxone, titrated to maintenance 4/1 mg to 24/6 mg once daily; administered sublingually as a single daily dose.. The standard adult dose of DEMADEX is: Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE and DEMADEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is classified as Category A/B. Pregnancy category C: First trimester: Limited data; no clear evidence of major malformations, but opioid exposure may be associated with neural tube defects in some studies. Secon. DEMADEX is classified as Category C. DEMADEX (torsemide) is a loop diuretic. Human data are limited. In animal studies, high doses caused fetal resorptions and maternal toxicity. First trimester: insufficient human da. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.